Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - Bespoke Extracts (OTC:BSPK), Black Diamond Therapeutic (NASDAQ:BDTX)

The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Black Diamond Therapeutics

  • The Trade: Black Diamond Therapeutics, Inc. BDTX 10% owner BB Biotech AG acquired a total of 400,000 shares an average price of $2.34. To acquire these shares, it cost around $934,080.
  • What’s Happening: Black Diamond Therapeutics presented dose escalation data demonstrating durable responses in patients with NSCLC from Phase 1 trial of BDTX-1535 at the AACR-NCI-EORTC International Conference.
  • What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies.

Bespoke Extracts

  • The Trade: Bespoke Extracts, Inc. BSPK CEO Michael Feinsod acquired a total of 3,000 shares at an average price of $0.20. To acquire these shares, it cost around $560.
  • What’s Happening: The company’s stock fell around 5% year-to-date.
  • What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.

Check This Out: Top 3 Materials Stocks You May Want To Dump This Month

Vivos

  • The Trade: Vivos Inc. RDGL CEO and President Micheal Korenko acquired a total of 100,000 shares at an average price of $0.05. The insider spent 5,360 to buy those shares.
  • What’s Happening: The company’s stock declined 22% over the past month.
  • What Vivos Does: Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors.

 

Don’t forget to check out our premarket coverage here




Image and article originally from www.benzinga.com. Read the original article here.